HCW Biologics Closes Exclusive Worldwide License for HCW11-006 with $7 Million Upfront Fee

HCW Biologics has closed an exclusive worldwide license for HCW11-006, a high potential fusion immunotherapeutic, with an upfront cash fee of $3.5 million and a $3.5 million in-kind payment. The licensee, Trimmune, is expected to initiate a Phase 1 clinical study in China by mid-2027. HCW Biologics has a "free" option to reclaim the rights to the Americas territory.